Steven Pieper - 28 Jul 2021 Form 4 Insider Report for XERIS PHARMACEUTICALS INC

Role
Chief Financial Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
28 Jul 2021
Net transactions value
$0
Form type
4
Filing time
29 Jul 2021, 18:06:37 UTC
Next filing
05 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +100,000 +170% $0.000000 158,858 28 Jul 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on July 28, 2022.

Remarks:

Chief Financial Officer